Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells

Nanomedicine

Volumn 7, Issue 1, 2012, Pages 39-53

  Kenzaoui, Blanka Halamoda ^a   Bernasconi, Catherine Chapuis ^a   Hofmann, Heinrich ^b   Juillerat Jeanneret, Lucienne ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

cell uptake; electron microscopy; human brain derived endothelial cells; iron oxide nanoparticles; magnetic enhancement; oxidative stress; transcellular transport

Indexed keywords

OLEIC ACID; POLYVINYL DERIVATIVE; POLYVINYLAMINE; REACTIVE OXYGEN METABOLITE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL SURVIVAL; CELLS, CULTURED; DEXTRANS; ENDOTHELIAL CELLS; HUMANS; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; MICROSCOPY, ELECTRON, TRANSMISSION; OLEIC ACID; OXIDATIVE STRESS; POLYVINYLS; REACTIVE OXYGEN SPECIES;

EID: 84555202693     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.85     Document Type: Article

References (49)

1. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nano Today 2, 22-32 (2007). (Pubitemid 46695431)
2. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifcations of drugs or drug-nanoparticles? Drug Discov. Today 13, 1099-1106 (2008).
3. Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system infammatory pathologies, a review. J. Cereb. Blood Flow Metab. 30, 15-35 (2010).
4. Bhaskar S, Tian F, Stoeger T et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 7, 3 (2010).
5. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 6, 12-21 (2010).
6. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66, 2873-2896 (2009).
7. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 311(5761), 622-627 (2006). (Pubitemid 43191298)
8. Xia T, Kovochich M, Brant J et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6, 1794-1807 (2006). (Pubitemid 44327550)
9. Møller P, Jacobsen NR, Folkmann JK et al. Role of oxidative damage in toxicity of particulates. Free Radical Res. 44, 1-46 (2010).
10. Naqvi S, Samim M, Abdin M et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int. J. Nanomed. 5, 983-989 (2010).
11. Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 26, 2685-2694 (2005). (Pubitemid 39600721)
12. Cengelli F, Maysinger D, Tschuddi-Monnet F et al. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J. Pharm. Exp. Ther. 318, 108-116 (2006).
13. Hanessian S, Grzyb JA, Cengelli F, Juillerat-Jeanneret L. Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs. Bioorg. Med. Chem. 16, 2921-2931 (2008). (Pubitemid 351418211)
14. Cengelli F, Grzyb JA, Montoro A, Hofmann H, Hanessian S, Juillerat-Jeanneret L. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem 4, 988-997 (2009).
15. Petri-Fink A, Steitz B, Finka A, Salaklang J, Hofmann H. Effect of cell media on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, cytotoxicity, and cellular uptake studies. Eur. J. Pharm. Biopharm. 68, 129-137 (2008). (Pubitemid 350181416)
16. Chastellain M, Petri A, Gupta A, Rao K V, Hofmann H. Superparamagnetic silica-iron oxide nanocomposites for application in hyperthermia. Adv. Eng. Mater. 6, 235-241 (2004).
17. Schaller V, Kräling U, Rusu C et al. Motion of nanometer sized magnetic particles in a magnetic feld gradient. J. Appl. Phys. 104, 093918 (2008).
18. Kamau Chapman S, Hassa PO, Steitz B et al. Enhancement of the effciency of non-viral gene delivery by application of pulsed magnetic feld. Nucleic Acids Res. 34, e40 (2006).
19. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target. 10, 327-335 (2002). (Pubitemid 34746314)
20. Gan C W, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-d-a-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31, 7748-7757 (2010).
21. Liu Y, Li J, Shao K et al. A leptin derived 30-amino-acid peptide modifed pegylated poly-l-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31, 5246-5257 (2010).
22. Tosi G, Vergoni AV, Ruozi B et al. Sialic acid and gylycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control Release 145, 49-57 (2010).
23. Huang R, Ke W, Han L et al. Brain-targeting mechanisms of lactoferrin-modifed DNA-loaded nanoparticles. J. Cereb. Blood Flow Metab. 29, 1914-1923 (2009).
24. Kreuter J, Shamenko D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10, 317-325 (2002). (Pubitemid 34746313)
25. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE et al. Brain targeting of nerve growth factor using poly(butylcyanoacrylate) nanoparticles. J. Drug Target. 17, 564-574 (2009).
26. Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J. Infuence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J. Microencaps. 23, 582-592 (2006). (Pubitemid 44446597)
27. Gelperina S, Khalansky A, Skidan IN et al. Toxicolological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126, 131-141 (2002). (Pubitemid 34075270)
28. Sarin H, Kanevsky AS, Wu H et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med. 6, 80-95 (2008).
29. Veiseh O, Sun C, Fang C et al. Specifc targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 69, 6200-6207 (2009).
30. Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L. The blood-brain barrier penetration and distribution of PEGylated fuorescein-doped magnetic silica nanoparticles in rat brain. Biochem. Biophys. Res. Commun. 394, 871-876 (2010).
31. Chang J, Jallouli Y, Kroubi M, Yuan XB et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm. 379, 285-292 (2009).
32. Weiss CK, Kohnle M W, Landfester K et al. The frst step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. Chem Med Chem 3, 1395-1403 (2008).
33. Petri B, Bootz A, Khalansky A et al. Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate)nanoparticles: revisiting the role of surfactant. J. Control Release 117, 51-58 (2007). (Pubitemid 46164866)
34. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: infuence of the formulation parameters. Eur. J. Pharm. Biopharm. 74, 157-163 (2010).
35. Meijas R, Perez-Yagüe S, Roca AG et al. Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles. Nanomedicine 5, 397-408 (2010).
36. Buyukhatipoglu K, Clyne AM. Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation. J. Biomed. Mater. Res. A 96(1), 186-195 (2011).
37. Apopa PL, Qian Y, Shao R et al. Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part. Fibre Toxicol. 6, 1 (2009).
38. Soenen SJH, Himmelreich U, Nuytten N, De Cuyper M. Cytotoxic effect of iron oxide nanoparticles and implications for safety of cell labeling. Biomaterials 32, 195-205 (2011).
39. Hekmatara T, Bernreuther C, Khalansky AS et al. Effcient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. Clin. Neuropathol. 28, 153-164 (2009).
40. Gil ES, Li J, Lowe TL. Quarternary ammonium b-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecues 10, 505-516 (2009).
41. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modifed nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71, 251-256 (2009).
42. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons. J. Control Release 137, 78-86 (2009).
43. Zensi A, Begley D, Pontikis C et al. Human serum albumin nanoparticles modifed with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J. Drug Target. 18, 842-848 (2010).
44. Wagner S, Kufeitner J, Zensi A et al. Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS ONE 5, e14213 (2010).
45. Cengelli F, Voinesco F, Juillerat-Jeanneret L. Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine 5, 1075-1087 (2010).
46. Fiaux H, Kuntz DA, Hoffman D et al. Functionalized pyrrolidine inhibitors of human a-mannosidases II in cancer: optimizing the ft to the active site. Bioorg. Med. Chem. 16, 7337-7346 (2008).
47. Lao F, Chen L, Li W et al. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit JNK-related apoptosis. ACS Nano 3, 3358-3368 (2009).
48. Liu HL, Hua MY, Yang HW et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc. Natl Acad. Sci. USA 107, 15205-15210 (2010).
49. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 31, 908-915 (2010).